Anthelminthic treatment: An adjuvant therapeutic strategy against Echinococcus granulosus

Parasitology International

Volumn 58, Issue 2, 2009, Pages 115-120

  Stamatakos, M ^a   Sargedi, C ^b   Stefanaki, Ch ^a   Safioleas, C ^a   Matthaiopoulou, I ^c   Safioleas, M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Ystad Hospital   (Sweden)

^c General Hospital of Tripolis   (Greece)

Author keywords

Benzoimidazole carbonates; Drug dosage; Echinococciasis; Efficacy; Recurrence

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B; ANTHELMINTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CARBAMAZEPINE; CIMETIDINE; FENBENDAZOLE; FLAVONOID; GENISTEIN; ISOFLAVONE DERIVATIVE; MEBENDAZOLE; NITAZOXANIDE; OXFENDAZOLE; PHENYTOIN; PRAZIQUANTEL; TIABENDAZOLE; TIZOXANIDE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALOPECIA; ANTHELMINTIC ACTIVITY; CHEMOTHERAPY; CYST; DISEASE PREDISPOSITION; DRUG MECHANISM; ECHINOCOCCOSIS; ECHINOCOCCUS GRANULOSUS; HEADACHE; HUMAN; HYDATIDIFORM MOLE; LEUKOPENIA; LIVER; LOOSE FECES; LUNG; MONITORING; NAUSEA; NEUTROPENIA; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THERAPY EFFECT; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; VOMITING; ANIMAL; DRUG EFFECTS; PARASITOLOGY; SECONDARY PREVENTION; TREATMENT OUTCOME;

ALBENDAZOLE; ANIMALS; ANTHELMINTICS; ECHINOCOCCOSIS; ECHINOCOCCUS GRANULOSUS; HUMANS; MEBENDAZOLE; RECURRENCE; TREATMENT OUTCOME; SECONDARY PREVENTION;

ECHINOCOCCUS GRANULOSUS;

EID: 64849093173     PISSN: 13835769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parint.2009.01.002     Document Type: Review

References (80)

1. Eckert J., and Deplazes P. Biological, epidemiological and clinical aspects of echinococcosis, a zoonosis of increasing concern. CMR 17 1 (2004) 107-135
2. Xiao N., Qiu J., Nakao M., Li T., Yang W., Chen X., et al. Echinococcus shiquicus, a new species from the Qinghai-Tibet plateau region of China: discovery and epidemiological implications. Parasitol Int 55 (2006) S233-236
3. Li T., Ito A., Nakayab K., Qiua J., Nakaob M., Xiaoa R.Z.N., et al. Species identification of human echinococcosis using histopathology and genotyping in northwestern China. Trans R Soc Trop Med Hyg 102 (2008) 585-590
4. Beggs I. The radiology of hydatid disease. Am J Roentgenol 145 (1985) 639-648
5. Schoretsanitis G., de Bree E., Melissas J., and Tsiftsis D. Primary hydatid cyst of the adrenal gland. Scand J Urol Nephrol 32 (1998) 51-53
6. WHO Informal Working Group. Guidelines for the treatment of cystic and alveolar echinococcosis in humans. Bull WHO 74 (1996) 231-242
7. Bekhti A., Schaaps J.P., Capron M., Dessaint J.P., Santoro F., and Capron A. Treatment of hepatic hydatid disease with mebendazole: preliminary results in four cases. Br Med J 2 (1977) 1047-1051
8. Tekin A., Kücükkartallar T., Kartal A., Kaynak A., Özer S., Tavli S., et al. Clinical and surgical profile and follow up of patients with liver hydatid cyst from an endemic region. J Gastrointestin Liver Dis 17 1 (2008) 33-37
9. Buttenschoen K., Gruener B., Carli Buttenschoen D., Reuter S., Henne-Bruns D., and Kern P. Palliative operation for the treatment of alveolar echinococcosis. Langenbeck's Arch Surg (2008) s00423-008-0367-6
10. Amir-Jahed A.K., Fardin R., Farzad A., and Bakshandeh K. Clinical echinococcosis. Ann Surg 182 (1975) 541
11. Little J.M., Hollands M.J., and Ekberg H. Recurrence of hydatid disease. World J Surg 12 5 (1988) 700-704
12. Todorov T. Epidemiology of echinococcosis in three districts of South Bulgaria. Diss. Ph. D., Medical Academy, Sofia, 1968: 183-206.
13. Mottaghian H., and Saidi F. Postoperative recurrence of hydatid disease. Br J Surg 65 (1978) 237-242
14. Falagas M.E., and Bliziotis I.A. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials. Am J Med Sci 334 3 (2007) 171-179
15. Morris D.L. Pre-operative albendazole therapy for hydatid cyst. Br J Surg 74 9 (1987) 805-806
16. Polat C., Dervisoglu A., Hokelek M., Yetim I., Buyukkarabacak Y., Ozkutuk Y., et al. Dual treatment of albendazole in hepatic hydatidosis: new therapeutic modality in 52 cases. J Gastroenterol Hepatol 20 (2005) 421-425
17. Filice C., and Brunetti E. Use of PAIR in human cystic echinococcosis. Acta Trop 64 1-2 (1997) 95-107
18. Khuroo M.S., Wani N.A., Javid G., Khan B.A., Yattoo G.N., Shah A.H., et al. Percutaneous drainage compared with surgery for hepatic hydatid cysts. N Engl J Med 337 13 (1997) 881-887
19. Liu Y.H., Wang X.G., and Yu D.G. Cerebral alveolar echinococcosis treated with albendazole. Trans R Soc Trop Med Hyg 87 4 (1993) 481
20. Karak P.K., Mittal M., Bhatia S., Mukhopadhyay S., and Berry M. Isolated cerebral hydatid disease with pathognomonic CT sign. Neuroradiology 34 (1992) 9-10
21. Gupta S.K., Tandon S.C., Khana S., and Asthana S. Case report: multiple intracranial hydatid cysts with post-operative dissemination. Clin Radiol 44 (1991) 203-204
22. Todorov T., Vutova K., Petkov D., Mechkov G., and Kolev K. Albendazole treatment of human cystic echinococcosis. Trans R Soc Trop Med Hyg 82 (1988) 453-459
23. Craig P.S., McManus D.P., Lightowlers M.W., Chabalgoity J.A., Garcia H.H., Gavidia C.M., et al. Prevention and control of cystic echinococcosis. Lancet Infect Dis 7 6 (2007) 385-394
24. El-On J. Benzimidazole treatment of cystic echinococcosis. Acta Trop 85 (2003) 243-252
25. Jimenez-Mejias M.E., Alarcon-Cruz J.C., Marquez-Rivas F.J., Palomino-Nicas J., Montero J.M., et al. Orbital hydatid cyst: treatment and prevention of recurrences with albendazole plus praziquantel. J Infect 41 (2000) 105-107
26. Ingold K., Bigler P., Thormann W., Cavaliero T., Gottstein B., and Hemphill A. Efficacies of albendazole sulfoxide and albendazole sulfone against in vitro-cultivated Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 43 5 (1999) 1052-1061
27. Marriner S.E., Morris D.L., Dickson B., and Bogan J.A. Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 30 (1986) 705-708
28. Ammann R.W., and Eckert J. Cestodes: Echinococcus. Gastroenterol. Clin North Am 25 (1996) 655-689
29. World Health Organization Office International des Epizooties. WHO/OIE manual on echinococcosis in humans and animals: a public health problem of global concern. World Organization for Animal Health (2001), Paris, France
30. Edwards G., and Breckenridge A.M. Clinical pharmacokinetics of anthelminthic drugs. Clin Pharmacokinet 15 (1988) 67-93
31. Cook G.C. Use of benzimidazole chemotherapy in human helminthiases: indications and efficacy. Parasitol Today 6 (1990) 133-136
32. Morris D.L., and Gould S. Serum and cyst concentrations of mebendazole and flubendazole in hydatid disease. BMJ 285 (1982) 175
33. Cotting J., Zeugin T., Steiger U., and Reichen J. Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis. Eur J Clin Pharmacol 38 (1990) 605-608
34. Mirfazaelian A., Rouini M.R., and Dadashzadeh S. Time dependent pharmacokinetics of albendazole in human. Biopharm Drug Dispos 24 (2003) 199-204
35. Kadry Z., Renner E.C., Bachmann L.M., Attigah N., Renner E.L., Ammann R.W., et al. Evaluation of treatment and long-term follow-up in patients with hepatic alveolar echinococcosis. Br J Surg 92 9 (2005) 1110-1116
36. Lidove O., Chauveheid M.P., Papo T., Vuitton D.A., Piarroux R., Hernigou A., et al. Echinococcus multilocularis massive pericardial infection: late and dramatic improvement under albendazole therapy. Am J Med 118 2 (2005) 195-197
37. Safioleas M.C., Misiakos E.P., Kouvaraki M., Stamatakos M.K., Manti C.P., and Felekouras E.S. Hydatid disease of the liver: a continuing surgical problem. Arch Surg 141 11 (2006) 1101-1108
38. Lange H., Eggers R., and Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 34 (1988) 315-317
39. Wen H., Zhang H.W., Muhmut M., Zou P.F., New R.R., and Craig P.S. Initial observation on albendazole in combination with cimetidine for the treatment of human cystic echinococcosis. Ann Trop Med Parasitol 88 (1994) 49-52
40. Saimot A.G., Meulemans A., Cremieux A.C., Giovanangeli M.D., Hay J.M., Delaitre B., et al. Albendazole as a potential treatment for human hydatidosis. Lancet 2 8351 (1983) 652-656
41. De Rosa F., Lastilla M.G., Franchi C., and Teggi A. Advances of medical treatment of human hydatidosis. Recent Prog Med 87 (1996) 346-352
42. Teggi A., Lastilla M.G., Grossi G., Franchi C., and De Rosa F. Increase of serum glutamic-oxaloacetic and glutamic-pyruvic transaminases in patients with hydatid cysts treated with mebendazole and albendazole. Mediterr J Infect Parasit Dis 10 (1995) 85
43. Opatrny L., Prichard R., Snell L., and Maclean J.D. Death related to albendazole-induced pancytopenia: case report and review. Am J Trop Med Hyg 72 3 (2005) 291-294
44. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology 121 (2000) S113-1S32
45. Steiger U., Cotting J., and Reichen J. Albendazole treatment of echinococcosis in humans: effects on microsomal metabolism and drug tolerance. Clin Pharmacol Ther 47 (1990) 347-353
46. Morris D., Jourdan J.-L., and Pourgholami M. Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia. Oncology 61 (2001) 42-46
47. Fernandez F., Rodriguez-Vidigal F., Ledesma V., Cabanillas Y., and Vagace J. Aplastic anemia during treatment with albendazole. Am J Hematol 53 (1996) 53-54
48. Dow G.S., O'Hara A.J., Newton S.C., Reynoldson J.A., and Thompson R.C. Plasmodium berghei: the antimalarial activity of albendazole in rats is mediated via effects on the hematopoietic system. Exp Parasitol 94 (2000) 259-263
49. Gargala G., Baishanbo A., Favennec L., Francois A., Ballet J.J., and Rossignol J.F. Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development. Antimicrob Agents Chemother 49 (2005) 4628-4634
50. Kraft C., Jenett-Siems K., Siems K., Gupta M.P., Bienzle U., and Eich E. Antiplasmodial activity of isoflavones from Andira inermis. J Ethanopharmacol 73 (2000) 131-135
51. Gilles H.M., and Hoffman P.S. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol 18 (2002) 95-97
52. Venkatesan P. Albendazole. J Antimicrob Chemother 41 (1998) 145-147
53. Wen H., New R.R., and Craig P.S. Diagnosis and treatment of human hydatidosis. Br J Clin Pharmacol 35 (1993) 565-574
54. Abu-Eshy S.A. Some rare presentations of hydatid cyst (Echinococcus granulosus). J R Coll Edinb 43 (1998) 347-352
55. Horton J. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop 64 (1997) 79-93
56. Little J.M. Hydatid disease at Royal Prince Alfred Hospital, 1964 to 1974. Med J Aust 1 (1976) 903-908
57. De Rosa F., and Teggi A. Mebendazole in human hydatidosis. Drugs Exp Clin Res 11 12 (1985) 875-878
58. Davis A., Pawlowski Z., and Dixon H. Multicentre clinical trials of benzoimidazole carbamates in human echinococcosis. Bull WHO 64 (1986) 383-388
59. Schantz P.M., Van Den Bossche H., and Eckert J. Chemotherapy for larval echinococcosis in animals and humans: report of a workshop. Z Parasitenkd 53 (1982) 5-26
60. De Rosa F., Teggi A., and Di Vico B. Influence of patient's age and cyst's age on the therapy of human hydatid disease with benzoimidazole carbamates. Turk J Med Biol Res 2 (1990) 70-74
61. Rostami Nejad M., Nazemalhosseini Mojarad E., Nochi Z., Fasihi Harandi M., Cheraghipour K., Mowlavi G.R., et al. Echinococcus granulosus strain differentiation in Iran based on sequence heterogeneity in the mitochondrial 12S rRNA gene. J Helminthol 82 (2008) 343-347
62. Rosenzvit M.C., Camicia F., Kamenetzky L., Muzulin P.M., Gutierrez A.M., et al. Identification and intra-specific variability analysis of secreted and membrane-bound proteins from Echinococcus granulosus. Parasitol Int 55 (2006) S63-67
63. Ben Nouir N., Nuñez S., Gianinazzi C., Gorcii M., Müller N., Nouri A., et al. Assessment of Echinococcus granulosus somatic protoscolex antigens for serological follow-up of young patients surgically treated for cystic Echinococcosis. J Clin Microb 5 (2008) 1631-1640
64. Siracusano A., Teggi A., Ioppolo S., Notargiacomo S., and De Rosa F. Lymphocyte transformation in patients with Echinococcus granulosus hydatid cysts treated with benzoimidazole carbamates: preliminary results. Ther Infect Dis 2 2 (1987) 137-139
65. Aceti A., Celestino D., Teggi A., Caferro M., Pennica A., Grilli A., et al. Histamine release test in the diagnosis of human hydatidosis. Clin Exp Allergy 19 3 (1989) 335-339
66. Arru E., Leoni A., and Garippa G. Chemoprophylaxis of hydatidosis in sheep. Arch Int Hidatid 30 (1991) 381-384
67. Müller E., Akovbiantz A., Ammann R.W., Bircher J., Eckert J., Wissler K., et al. Treatment of human echinococcosis with Mebendazole. Preliminary observations in 28 patients. Hepato-Gastroenterol. 29 (1982) 236-239
68. Teggi A., Lastilla M.G., and De Rosa F. Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob Agents Chemother 37 (1993) 1679-1684
69. Morris D.L. Albendazole treatment of hydatid disease-follow-up at 5 years. Trop Doctor 19 (1989) 179-180
70. el-Mufti M., Kamag A., Ibrahim H., Taktuk S., Swaisi I., Zaidan A., et al. Albendazole therapy of hydatid disease: 2 years follow-up of 40 cases. Ann Trop Med Parasitol 87 (1993) 241-246
71. Nahmias J., Goldsmith R.S., Soibelman M., and El-On J. Three to seven year follow up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease). Ann Trop Med Parasitol 88 (1994) 295
72. Blanton R.E., Wachira T.M., Zeyhle E.E., Njoroge E.M., Magambo J.K., and Schantz P.M. Oxfendazole treatment for cystic hydatid disease in naturally infected animals. Antimicrob Agents Chemother 42 (1998) 601-605
73. Ali R., Ozkalemkas F., Ozkocaman V., Ozcelik T., Akalin H., Ozkan A., et al. Hydatid disease in acute leukaemia: effect of anticancer treatment on echinococcosis. Microbes Infect 7 (2005) 1073-1074
74. Walker M., Rossignol J.F., Torgerson P., and Hemphill A. In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. J Antimicrob Chemother 54 (2004) 609-616
75. Rossignol J.F., and Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana. Am J Trop Med Hyg 33 (1984) 511-512
76. Stettler M., Rossignol J.F., Fink R., Walker M., Gottstein B., Merli M., et al. Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int J Parasitol 34 (2004) 615-624
77. Stettler M., Fink R., Walker M., Gottstein B., Geary T.G., Rossignol J.F., et al. In vitro parasiticidal effect of nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 47 (2003) 467-474
78. Walker M., Rossignol J.F., Torgerson P., and Hemphill A. Hemphill In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. J Antimicrob Chemother 54 (2004) 609-616
79. Das B., Tandon V., and Saha N. Effects of phytochemicals of Flemingia vestita (Fabaceae) on glucose 6-phosphate dehydrogenase and enzymes of gluconeogenesis in cestode (Raillietina echinobothria). Comp Biochem Physiol 139 (2004) 141-146
80. Naguleswaran A., Spicher M., Vonlaufen N., Ortega-Mora L.M., Torgerson P., Gottstein B., et al. In vitro metacestodicidal activities of genistein and other isoflavones against Echinococcus multilocularis and Echinococcus granulosus. Antimicrob Agents Chemother 11 (2006) 3770-3778